Business
Virax Biolabs Group Limited Announces Purchase Order to Launch COVID-19 and Influenza A+B Antigen Combo Rapid Tests with Cosmos Health (NASDAQ:COSM)
LONDON, Feb. 7, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the
About this update from Virax Biolabs Group Limited
[{"type":"text","content":"LONDON, Feb. 7, 2023 /PRNewswire/ -- Virax Biolabs Group Limited (\"Virax\" or the \"Company\") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced that it has signed a Purchase Order with Cosmos Health (Nasdaq: COSM) (\"Cosmos\") to launch and market COVID-19 and Influenza A+B Antigen Combo Rapid Detection Kits. Pursuant to their previously signed distribution agreement dated September 2022, Cosmos will have exclusive distribution rights for Greece and Cyprus, with the opportunity to distribute the ViraxClear branded test kits across Europe on a non-exclusive basis.\n\n \n \n \n \n \n \n\n \nVirax's Chairman of the Board of Directors and Chief Executive Officer, Mr. James Foster, commented, \"COVID-19, Influenza A and Influenza B are major sources of illness and mortality in humans across the globe. We are pleased to offer a dual solution, that can accurately identify infections related to these viruses, with results typically available in 15 minutes, and improve health outcomes through early identification.\"\n\"COVID-19 continues to threaten lives across the world. According to the World Health Organization (\"WHO\"), as of February 2, 2023, there have been approximately 750 million confirmed COVID-19 cases and about 7 million COVID-19-attributable deaths,\"1 said Mr. Greg Siokas, Chief Executive Officer of Cosmos. \"While the threat of Influenza has been overshadowed by COVID-19, the healthcare burden of Influenza should not be overlooked. WHO reports that Influenza infections result in roughly 5 million cases of severe illness and approximately 650,000 respiratory deaths worldwide each year.2 Therefore, we are excited to partner with Virax to bring much needed dual testing solutions to Greece and Cyprus as well as expanding into additional territories going forward.\"\nThe COVID-19 & Influenza A+B antigen combo rapid test is a single-use test kit intended for qualitative detection of nucleocapsid protein antigen of Influenza A and B viral antigens and COVID-19 antigen from nasal swab specimens.\nAbout Virax Biolabs Group Limited\nFounded in 2013, Virax Biolabs Group Limited is an innovative diagnostics company focused on the prevention, detection and diagnosis of viral diseases, with a particular interest in the field of immunology.\nIn addition ...